Assessment of the frequency of emergence, as defined by the presence of the H275Y mutation during oseltamivir therapy in inuenza A.

Trial Profile

Assessment of the frequency of emergence, as defined by the presence of the H275Y mutation during oseltamivir therapy in inuenza A.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Oseltamivir (Primary)
  • Indications Influenza A virus infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 30 Jun 2017 New trial record
    • 05 Jun 2017 Results presented at the ASM Microbe 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top